Satellos Bioscience Inc. MSCLF
6.25 USD 0.00 (+0.00%)
Apr 8, 2026, 9:30 AM EDT
5.77 Day range 6.39
0.88 52-week range 12.50
- YTD
- +6.29%
- 1 year
- -5.16%
News
marketbeat.com Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results Satellos Bioscience NASDAQ: MSLE said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living with Duchenne…
globenewswire.com Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback TORONTO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage biotechnology company developing potentially life-improving medicines to treat…